Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

2.4K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

503
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
503
Amyloid Fibrils03:03

Amyloid Fibrils

11.5K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.5K
Amyloid Fibrils03:03

Amyloid Fibrils

6.2K
6.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The collection of speech data for the assessment of cognition remotely: Balancing ethical and practical challenges.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Spiro-Linked Polyketides from Cultures of <i>Westerdykella dispersa</i> Ca4-13 as Inhibitors of iNOS-Associated Neuroinflammation.

Journal of natural products·2026
Same author

Benzydamine Attenuates Matrix Metalloproteinase-9 Expression Through Inhibition of ERK MAPK in Activated Human Monocytic Cells Under Hyperglycemic Condition.

Mediators of inflammation·2026
Same author

Evaluating physicians' teaching perspectives and demonstration of core competencies in clinical shadowing.

BMC medical education·2025
Same author

Aging-associated immune signature as a predictor of mortality in end-stage renal disease: results from the longitudinal iESRD study.

Immunity & ageing : I & A·2025
Same author

Anti-herpetic treatment reduces dementia risk: A systematic review and meta-analysis.

Journal of Alzheimer's disease : JAD·2025
Same journal

Stage-dependent relationship between sleep duration and cortical tau deposition in cognitively impaired individuals: A cross-sectional study.

Journal of Alzheimer's disease : JAD·2026
Same journal

Multilayer brain connectivity and long-term cognitive changes in individuals at risk for Alzheimer's disease.

Journal of Alzheimer's disease : JAD·2026
Same journal

The creation and verification of a detection model for mild cognitive impairment by employing eye-tracking and gait metrics.

Journal of Alzheimer's disease : JAD·2026
Same journal

Compartment-specific analysis reveals disrupted astrocytic calcium transients in anesthetized Alzheimer's disease mice.

Journal of Alzheimer's disease : JAD·2026
Same journal

<i>APOE</i> ε4-specific associations between agitation, cerebrospinal fluid biomarkers, and cognitive decline in cognitively impaired patients.

Journal of Alzheimer's disease : JAD·2026
Same journal

Depressive-cognitive interactions modulate amygdala and hippocampus functional connectivity in mild cognitive impairment.

Journal of Alzheimer's disease : JAD·2026
查看所有相关文章

相关实验视频

Updated: Jan 8, 2026

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

4.5K

粉样蛋白负担,胆固醇完整性和认知功能之间的关系.

Li-Hua Lee1, Chia-Ju Chou1, Yao-Chia Shih2

  • 1Department of Neurology, Cardinal Tien Hospital, New Taipei City, Taiwan.

Journal of Alzheimer's disease : JAD
|December 22, 2025
PubMed
概括
此摘要是机器生成的。

胆固醇白质完整性与阿尔茨海默氏症早期的粉样蛋白积累有关,影响认知功能. 这种关联在非载体的阿波利波蛋白E4基因中更为明显.

关键词:
阿尔茨海默病的疾病阿尔茨海默病的疾病.粉样蛋白负担是什么作为阿波利波蛋白E4载体的载体.胆固醇的完整性 胆固醇的完整性认知 认知 认知

更多相关视频

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.6K
Intracerebroventricular Injection of Amyloid-&#946; Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

44.1K

相关实验视频

Last Updated: Jan 8, 2026

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

4.5K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.6K
Intracerebroventricular Injection of Amyloid-&#946; Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

44.1K

科学领域:

  • 神经科学是一个神经科学.
  • 放射学 放射学是一门学科.
  • 老年学是一门学科.

背景情况:

  • 粉样蛋白积累和胆固醇白质变性是早期阿尔茨海默病 (AD) 的标志.
  • 在阿尔茨海默病的发病过程中,粉样蛋白负担与胆固醇通路完整性之间的确切关系尚未完全理解.

研究的目的:

  • 为了调查粉样蛋白积累,胆固醇白质通路完整性和早期AD的认知表现之间的联系.
  • 探索阿波利波蛋白E4 (APOE4) 基因型如何影响这些关系.

主要方法:

  • 对109名参与者进行的横截面研究 (37人为对照组,72人为早期AD).
  • 神经心理学测试 (MMSE,CDR-SB,口语流).
  • 扩散张力成像 (DTI) 检测胆固醇白质完整性和粉样蛋白质负荷的粉样蛋白质正子辐射断层扫描 (PET).

主要成果:

  • 粉样蛋白负担和胆固醇完整性独立地与所有参与者的认知表现相关.
  • 在AD早期,粉样蛋白负担与MMSE相关,胆固醇完整性与所有认知指标相关.
  • 粉样蛋白负荷和胆固醇完整性仅在非载体APOE4中显著相关.

结论:

  • 胆固醇白质完整性受到粉样蛋白负担的影响,可以作为早期阿尔茨海默病的特定成像生物标志物.
  • 这种关联在没有APOE4基因变异的个体中尤为明显.